| [1] |
中华医学会心血管病学分会，中国医师协会心血管内科医师分会，中国医师协会心力衰竭专业委员会，等.中国心力衰竭诊断和治疗指南2024[J].中华心血管病杂志，2024，52（3）：235-275.
|
| [2] |
Nakamura T, Hosoyama T, Kawamura D, et al. Influence of aging on the quantity and quality of human cardiac stem cells[J]. Sci Rep, 2016, 6:22781.
|
| [3] |
Chen J, Xiao X, Zhou C, et al. The dark side of vascular aging: Noncoding ribonucleic acids in heart failure with preserved ejection fraction[J]. Cells, 2025, 14(16):1269.
|
| [4] |
Miao L, Liu YL. Research advances in targeted therapy for heart failure[J]. Rev Cardiovasc Med, 2023, 24(10):276.
|
| [5] |
Wang X, Zhang C. Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021)[J]. Aging Med (Milton), 2022, 5(2):78-93.
|
| [6] |
中华医学会老年医学分会心血管疾病学组，《老年慢性心力衰竭诊治中国专家共识》编写组.老年人慢性心力衰竭诊治中国专家共识（2021）[J].中华老年医学杂志，2021，40（5）：550-561.
|
| [7] |
Triposkiadis F, Xanthopoulos A, Butler J. Cardiovascular aging and heart failure: JACC review topic of the week[J]. J Am Coll Cardiol, 2019, 74(6):804-13.
|
| [8] |
Li A, Yan J, Zhao Y, et al. Vascular aging: Assessment and intervention[J]. Clin Interv Aging, 2023, 18:1373-1395.
|
| [9] |
中华医学会老年医学分会心血管学组.血管衰老临床评估与干预中国专家共识（2018）[J].中华老年病研究电子杂志，2019，6（1）：1-8.
|
| [10] |
Gyöngyösi H, Kőrösi B, Batta D, et al. Comparison of SCORE, SCORE2 and Framingham risk score-based methods for vascular age calculation [J]. J Clin Med, 2025, 14(21):7570.
|
| [11] |
van den Berg PF, Yousif LI, Koop Y, et al. Framingham risk score associates with incident cancer and heart failure[J]. Eur J Prev Cardiol, 2025, 33(4):490-497.
|
| [12] |
álvarez-Bueno C, Cavero-Redondo I, Bruno RM, et al. Intima media thickness and cognitive function among adults: Meta-analysis of observational and longitudinal studies[J]. J Am Heart Assoc, 2022, 11(5):e021760.
|
| [13] |
Akinmolayan A, Papacosta AO, Lennon LT, et al. Carotid intima-media thickness, carotid distensibility, and incident heart failure in older men: The British regional heart study[J]. J Am Heart Assoc, 2025, 14(7):e037167.
|
| [14] |
Laurent S, Marais L, Boutouyrie P. The noninvasive assessment of vascular aging[J]. Can J Cardiol, 2016, 32(5):669-679.
|
| [15] |
Golan N, Brzezinski RY, Slieman M, et al. Routine Ankle-Brachial index (ABI) measurement: A window into atherosclerosis and early left ventricular dysfunction in patients diagnosed with cancer[J]. Cardiooncology, 2024, 10(1):60.
|
| [16] |
Cai GF, Chen SW, Huang JK, et al. Decoding marker genes and immune landscape of unstable carotid plaques from cellular senescence[J]. Sci Rep, 2024, 14(1):26196.
|
| [17] |
Ungvari Z, Tarantini S, Sorond F, et al. Mechanisms of vascular aging, a geroscience perspective[J]. J Am Col Cardiol, 2020, 75(8):931-41.
|
| [18] |
Dutta D, Calvani R, Bernabei R, et al. Contribution of impaired mitochondrial autophagy to cardiac aging: Mechanisms and therapeutic opportunities[J]. Circ Res, 2012, 110(8):1125-1138.
|
| [19] |
Gao W, Wang X, Zou Y, et al. Progress in the application of novel inflammatory indicators in chronic kidney disease[J]. Front Med (Lausanne), 2025, 12:1500166.
|
| [20] |
Peoples JN, Saraf A, Ghazal N, et al. Mitochondrial dysfunction and oxidative stress in heart disease[J]. Exp Mol Med, 2019, 51(12):1-13.
|
| [21] |
Khavinson V, Linkova N, Dyatlova A, et al. Senescence-associated secretory phenotype of cardiovascular system cells and inflammaging: Perspectives of peptide regulation[J]. Cells, 2022, 12(1):106.
|
| [22] |
Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease[J]. Nat Rev Cardiol, 2013, 10(5):274-283.
|
| [23] |
Palombo C, Kozakova M. Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications[J]. Vascul Pharmacol, 2016, 77:1-7.
|
| [24] |
Herzog MJ, Müller P, Lechner K, et al. Arterial stiffness and vascular aging: Mechanisms, prevention, and therapy[J]. Signal Transduct Target Ther, 2025, 10(1):282.
|
| [25] |
Chirinos JA, Segers P, Hughes T, et al. Large-artery stiffness in health and disease: JACC State-of-the-art review[J]. J Am Coll Cardiol, 2019, 74(9):1237-1263.
|
| [26] |
中华医学会心血管病学分会.冠状动脉微血管疾病诊断和治疗中国专家共识（2023版） [J].中华心血管病杂志，2024，52（5）：460-492.
|
| [27] |
Lee C, Kim MJ, Kumar A, et al. Vascular endothelial growth factor signaling in health and disease: From molecular mechanisms to therapeutic perspectives[J]. Signal Transduct Target Ther, 2025, 10(1):170.
|
| [28] |
Paneni F, Diaz Cañestro C, Libby P, et al. The aging cardiovascular system: Understanding it at the cellular and clinical levels[J]. J Am Coll Cardiol, 2017, 69(15):1952-1967.
|
| [29] |
Zheng L, Chen X, He X, et al. Mettl4-mediated mitochondrial DNA N6-Methyldeoxyadenosine promoting macrophage inflammation and atherosclerosis[J]. Circulation, 2025, 151(13):946-965.
|
| [30] |
Kennel PJ, Schulze PC. A review on the evolving roles of MiRNA-based technologies in diagnosing and treating heart failure[J]. Cells, 2021, 10(11):3191.
|
| [31] |
Artimovič P, Špaková I, Macejková E, et al. The ability of microRNAs to regulate the immune response in ischemia/reperfusion inflammatory pathways[J]. Genes Immun, 2024, 25(4):277-296.
|
| [32] |
Fan Y, Zheng Y, Zhang Y, et al. ARID5A orchestrates cardiac aging and inflammation through MAVS mRNA stabilization [J]. Nat Cardiovasc Res, 2025, 4(5):602-623.
|
| [33] |
Suda M, Katsuumi G, Tchkonia T, et al. Potential clinical implications of senotherapies for cardiovascular disease[J]. Circ J, 2024, 88(3):277-284.
|
| [34] |
Shimizu I. Exploration of new therapies for heart failure targeting age-related mechanisms[J]. Circ J, 2024, 88(5):626-630.
|
| [35] |
Wang L, Cheng CK, Yi M, et al. Targeting endothelial dysfunction and inflammation[J]. J Mol Cell Cardiol, 2022, 168:58-67.
|
| [36] |
中华医学会心血管病学分会，中华心血管病杂志编辑委员会.血管紧张素受体-脑啡肽酶抑制剂在心力衰竭患者中应用的中国专家共识[J].中华心血管病杂志，2022，50（7）：662-670.
|
| [37] |
Correale M, Mazzeo P, Mallardi A, et al. Switch to SGLT2 inhibitors and improved endothelial function in diabetic patients with chronic heart failure[J]. Cardiovasc Drugs Ther, 2022, 36(6):1157-1164.
|
| [38] |
Yan Y, Liu B, Du J, et al. SGLT2i versus ARNI in heart failure with reduced ejection fraction: A systematic review and meta-analysis[J]. ESC Heart Fail, 2021, 8(3):2210-2219.
|
| [39] |
Song R, Qian H, Wang Y, et al. Research progress on the cardiovascular protective effect of glucagon-like peptide-1 receptor agonists[J]. J Diabetes Res, 2022, 2022:4554996.
|
| [40] |
Zhang F, Zhang L, Hu G, et al. Rectifying METTL4-mediated N(6)-methyladenine excess in mitochondrial dna alleviates heart failure[J]. Circulation, 2024, 150(18):1441-1458.
|
| [41] |
Fuertes-Kenneally L, Manresa-Rocamora A, Blasco-Peris C, et al. Effects and optimal dose of exercise on endothelial function in patients with heart failure: A systematic review and meta-analysis[J]. Sports Med Open, 2023, 9(1):8.
|
| [42] |
Granger BB, Tulsky JA, Kaufman BG, et al. Polypharmacy in palliative care for advanced heart failure: The PAL-HF experience[J]. J Card Fail, 2022, 28(2):334-338.
|